
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Entelexo Biotherapeutics is headquartered in Irvine, CA.
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Autoimmune diseases like Rheumatoid Arthritis, Crohn's Disease, and Psoriasis affect millions and remain uncured, and existing treatments are one-size-fits-all drugs that block only a single cytokine, failing to address the multiple cell types and pathways actually involved.
Entelexo engineers therapeutic exosomes on a proprietary platform that can communicate with multiple specific diseased cell types simultaneously, rapidly prototyping and de-risking candidates using human cell assays.
The company claims its rational engineering platform can rapidly create and fine-tune indication-specific exosome treatments that target multiple cell types at once, backed by a growing patent portfolio, YC acceptance/graduation, and efficacy data from human cell immunoassays.
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 27, 2026.